TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

NCT07487662 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

DRUG: sintilimab
DRUG: ipilimumab N01
DRUG: Lenvatinib
PROCEDURE: TACE
PROCEDURE: ablation

Sponsor

Sun Yat-sen University

Collaborators

[object Object]